Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Oncotarget. 2014 Jul 30;5(14):5320-34.

Functional genomics identifies novel genes essential for clear cell renal cell carcinoma tumor cell proliferation and migration.

Author information

1
Department of Cancer Biology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.
2
Incogen, Inc., Jacksonville, Florida.
3
Department of Pharmacology and Molecular Sciences, Johns Hopkins School of Medicine, Jacksonville, Florida.
4
MUSC Proteomics Center, Jacksonville, Florida.
5
Division of Hematology and Oncology, Mayo Clinic Comprehensive Cancer Center, Jacksonville, Florida.

Abstract

Currently there is a lack of targeted therapies that lead to long-term attenuation or regression of disease in patients with advanced clear cell renal cell carcinoma (ccRCC). Our group has implemented a high-throughput genetic analysis coupled with a high-throughput proliferative screen in order to investigate the genetic contributions of a large cohort of overexpressed genes at the functional level in an effort to better understand factors involved in tumor initiation and progression. Patient gene array analysis identified transcripts that are consistently elevated in patient ccRCC as compared to matched normal renal tissues. This was followed by a high-throughput lentivirus screen, independently targeting 195 overexpressed transcripts identified in the gene array in four ccRCC cell lines. This revealed 31 'hits' that contribute to ccRCC cell proliferation. Many of the hits identified are not only presented in the context of ccRCC for the first time, but several have not been previously linked to cancer. We further characterize the function of a group of hits in tumor cell invasion. Taken together these findings reveal pathways that may be critical in ccRCC tumorigenicity, and identifies novel candidate factors that could serve as targets for therapeutic intervention or diagnostic/prognostic biomarkers for patients with advanced ccRCC.

PMID:
24979721
PMCID:
PMC4170622
DOI:
10.18632/oncotarget.2097
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Impact Journals, LLC Icon for PubMed Central
Loading ...
Support Center